z-logo
Premium
Failure of complete suppression of endogenous glucose production by euglycaemic hyperinsulinaemia in normal humans
Author(s) -
NEELY R. D. G.,
HARPER R.,
ROONEY D. P.,
ENNIS C. N.,
BELL P. M.,
TRIMBLE E. R.
Publication year - 1995
Publication title -
european journal of clinical investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.164
H-Index - 107
eISSN - 1365-2362
pISSN - 0014-2972
DOI - 10.1111/j.1365-2362.1995.tb01728.x
Subject(s) - medicine , endocrinology , basal (medicine) , insulin , glucose clamp technique , endogeny , hyperinsulinemia , insulin resistance , pancreatic hormone , chemistry , biology
. In normal subjects, endogenous glucose production (EGP) is usually assumed to be completely suppressed during euglycaemic clamp studies performed at high insulin levels (>100 mU L ‐1 ). However, this assumption is based on non‐steady‐state tracer measurements of EGP which are prone to negative errors. We have used purified [6‐ 3 H]glucose in an optimal tracer infusion protocol to assess the suppression of EGP during 4 h euglycaemic clamps in eight normal men. An insulin infusion rate of 5 mU kg ‐1 min ‐1 was chosen to achieve supraphysiological (> 500 mU L ‐1 ) plasma insulin concentrations. Using a labelled exogenous glucose infusion, plasma glucose (mean ± SEM 5.3 ± 0.1 mmol L ‐1 ) and glucose specific activities (mean 100 ± 3% of basal) were maintained constant from 80 to 240 min. During hyperinsulinaemia, isotopically determined glucose appearance rates (Ra) were greater than glucose infusion rates (GIR) throughout the euglycaemic clamp period ( P <0.001) and EGP (Ra‐GIR) was always greater than zero. In seven of the eight subjects studied EGP was partly suppressed but showed a wide variation (EGP 5 to 91% of basal at 80–120 min and 12 to 87% of basal at 200–240 min) while in one subject EGP rose above basal (by 72% at 80–120 min and 49% at 200–240 min). We conclude that EGP is not completely suppressed during euglycaemic clamps at high insulin levels.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here